DRG Market Assessment reports

Clarivate Epidemiology’s coverage of glioma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the incidence of glioma for each country, as well…

In 2021, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $130 billion in the major pharmaceutical markets under study (United…

In 2020, sales of branded biologics in ophthalmology reached over $8.50 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2020-2030 forecast period,…

In 2020, sales of branded biologics for respiratory indications reached nearly $1.50 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2020-…

In 2020, sales of insulins at the ex-manufacturer price level exceeded $11 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2020-2030 forecast…

In 2020, sales of erythropoiesis-stimulating agent (ESA) brands and biosimilars at the ex-manufacturer price level totaled almost $4.18 billion in the major pharmaceutical markets under study (…

In 2020, sales of branded biologics in immunology exceeded $70 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this…

In 2020, sales of branded MAb biologics in oncology exceeded $30 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $3…

In 2021, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $130 billion in the major pharmaceutical markets under study (United…

For neurologists, established molecules like leveteriacetam, lamotrigine, and carbamazepine remain the first choice of treatment for epilepsy; however, the new entrants in the market are evoloving…

Sickle cell disease (SCD) is a rare genetic blood disorder characterized by polymerization of hemoglobin in red blood cells that distorts them into a sickle shape. This sickling leads to several…

Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in non-small-cell lung cancer (NSCLC), breast cancer, and colorectal cancer. Biomarker-…